Oncology Drugs Market Analysis

ID: MRFR/Pharma/10833-HCR

135 Pages

Kinjoll Dey

February 2026

Oncology Drugs Market Research Report: Size, Share, Trend Analysis By Drug Type (Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Hormonal Therapy Drugs), By Therapeutic Area (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Leukemia), By Route of Administration (Oral, Intravenous, Subcutaneous, Intramuscular), By Patient Demographics (Adult, Pediatric, Geriatric) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Request Free Sample

Summary Table of Contents Segmentation Download PDF

Market Analysis

In-depth Analysis of Oncology Drugs Market Industry Landscape

The oncology drugs market is a dynamic and rapidly changing sector of the pharmaceutical industry that is involved in research, development, and commercialization of medicines for treating various cancer types. The dynamics of oncology drugs are determined by the interplay between scientific discoveries, regulatory requirements, economic factors as well as demographic changes that shape cancer management globally.

Scientific innovation drives the oncology drugs market. This has seen targeted therapies and immunotherapies developed due to better understanding of genetics and molecular biology underlying cancer. In this case, precision medicine aims at killing only malignant cells but leaving normal ones undisturbed thus making these forms of therapy more efficient as well as less harmful. Continual discovery of new drug targets alongside innovations in drug delivery systems further make Oncology Drugs Market dynamic.

In addition, the competitive nature within the oncology drugs market implies that it includes both multinational giant pharma companies and small biotech firms. This is done through mergers and acquisitions as well as collaborations which enhance their respective portfolios for oncology medicines while developing research capabilities to be useful in expanding their markets. It creates an environment for competitors where many therapies can be discovered leading to different treatment options being available to patients with this condition.

In conclusion, factors such as the aging demographic and rising rates of cancer contribute to the overall growth of the oncology drugs market. The increase in incidence of cancers related conditions prompts demand for better treatment options, thus creating room for pharmaceutical companies to address various forms of cancers. Moreover, the personalized nature of many oncology drug treatments aligns perfectly with the increasing focus on precision medicine, wherein treatments are designed based on individual patient characteristics.

Market Highlights

Author

Kinjoll Dey

Research Analyst Level I

He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Get In Touch

FAQs

What is the current valuation of the Oncology Drugs Market as of 2024?

The Oncology Drugs Market was valued at 177.1 USD Billion in 2024.

What is the projected market valuation for the Oncology Drugs Market in 2035?

The market is projected to reach 763.21 USD Billion by 2035.

What is the expected CAGR for the Oncology Drugs Market during the forecast period 2025 - 2035?

The expected CAGR for the Oncology Drugs Market during 2025 - 2035 is 14.2%.

Which companies are considered key players in the Oncology Drugs Market?

Key players include Roche, Bristol-Myers Squibb, Merck & Co., Novartis, Pfizer, AstraZeneca, Johnson & Johnson, Amgen, and Gilead Sciences.

What are the major segments of the Oncology Drugs Market by type?

The major segments by type include Chemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, and Hormonal Therapy Drugs.

How do the revenues of Targeted Therapy Drugs compare to those of Chemotherapy Drugs?

Targeted Therapy Drugs are projected to generate revenues of 250.0 USD Billion, surpassing Chemotherapy Drugs at 190.0 USD Billion.

What is the revenue projection for Immunotherapy Drugs by 2035?

Immunotherapy Drugs are expected to reach a valuation of 220.0 USD Billion by 2035.

Which therapeutic area is projected to have the highest revenue in the Oncology Drugs Market?

Lung Cancer is projected to generate the highest revenue, reaching 180.0 USD Billion by 2035.

What is the expected revenue for Pediatric oncology drugs by 2035?

Pediatric oncology drugs are projected to reach a valuation of 120.0 USD Billion by 2035.

What routes of administration are most prevalent in the Oncology Drugs Market?

The most prevalent routes of administration include Intravenous, Oral, Subcutaneous, and Intramuscular.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

As per Market Research Future analysis, the Oncology Drugs Market was estimated at 177.1 USD Billion in 2024. The oncology industry is projected to grow from 202.26 USD Billion in 2025 to 763.21 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 14.2% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Oncology Drugs Market is experiencing robust growth driven by innovative therapies and increasing cancer prevalence.

The rise of targeted therapies is reshaping treatment paradigms in oncology. Immunotherapy is expanding rapidly, particularly in the Asia-Pacific region, which is the fastest-growing market. Combination therapies are gaining traction as they enhance treatment efficacy across various cancer types. The growing incidence of cancer and advancements in precision medicine are key drivers propelling market expansion.

Oncology Drugs Market

CAGR

14.20%

Market Size & Forecast

2024 Market Size	177.1 (USD Billion)
2035 Market Size	763.21 (USD Billion)
CAGR (2025 - 2035)	14.20%
Largest Regional Market Share in 2024	North America

Major Players

Roche (CH), Bristol-Myers Squibb (US), Merck & Co. (US), Novartis (CH), Pfizer (US), <a href="https://www.astrazeneca.com/our-therapy-areas/oncology/medicines-portfolio-and-pipeline.html">AstraZeneca </a>(GB), Johnson & Johnson (US), Amgen (US), Gilead Sciences (US)

Market Trends

The Oncology Drugs Market is currently experiencing a dynamic evolution, driven by advancements in research and development, as well as an increasing understanding of cancer biology. Pharmaceutical companies are focusing on innovative therapies, including targeted treatments and immunotherapies, which appear to offer improved efficacy and reduced side effects compared to traditional chemotherapy. This shift towards personalized medicine is reshaping treatment paradigms, as healthcare providers seek to tailor therapies to individual patient profiles. Furthermore, the growing prevalence of cancer globally is prompting a surge in demand for effective oncology drugs, leading to heightened competition among manufacturers. In addition, regulatory agencies are adapting to the rapid pace of innovation, streamlining approval processes for new oncology drugs. This regulatory flexibility may facilitate quicker access to novel therapies for patients, potentially transforming the treatment landscape. Collaborations between biotech firms and established pharmaceutical companies are also becoming more common, as they aim to leverage complementary strengths in drug development. Overall, the Oncology Drugs Market is poised for continued growth, with a focus on innovative solutions that address unmet medical needs and improve patient outcomes.

Rise of Targeted Therapies

The Oncology Drugs Market is witnessing a notable increase in the development and adoption of targeted therapies. These treatments are designed to specifically attack cancer cells while sparing healthy tissue, which may lead to fewer side effects and improved patient quality of life. As research progresses, the identification of specific biomarkers is enhancing the ability to match patients with the most effective therapies, thereby optimizing treatment outcomes.

Expansion of Immunotherapy

Immunotherapy is emerging as a transformative approach within the Oncology Drugs Market. By harnessing the body's immune system to combat cancer, these therapies are showing promise in treating various malignancies. The growing body of evidence supporting the efficacy of immunotherapeutic agents is likely to drive further investment and research, potentially leading to new treatment options for patients.

Increased Focus on Combination Therapies

Combination therapies are gaining traction in the Oncology Drugs Market as a strategy to enhance treatment efficacy. By utilizing multiple agents that target different pathways, these approaches may overcome resistance mechanisms and improve overall patient outcomes. This trend reflects a broader understanding of cancer as a complex disease, necessitating multifaceted treatment strategies.

Oncology Drugs Market Market Drivers

Growing Incidence of Cancer

The rising incidence of cancer worldwide is a primary driver of the Oncology Drugs Market. According to recent statistics, cancer cases are projected to increase significantly, with estimates suggesting that by 2040, the number of new cancer cases could reach 29.5 million annually. This alarming trend necessitates the development and availability of effective oncology drugs, thereby propelling market growth. The increasing prevalence of risk factors such as obesity, smoking, and an aging population further exacerbates this situation. As healthcare systems strive to address this growing burden, investments in oncology drug research and development are likely to intensify, fostering innovation and expanding treatment options within the Oncology Drugs Market.

Advancements in Precision Medicine

Advancements in precision medicine are transforming the Oncology Drugs Market by enabling more personalized treatment approaches. The integration of genomic profiling and biomarker testing allows for the identification of specific cancer types and their unique characteristics. This tailored approach not only enhances treatment efficacy but also minimizes adverse effects, leading to improved patient outcomes. The market for precision oncology drugs is expected to witness substantial growth, with projections indicating a compound annual growth rate of over 10% in the coming years. As healthcare providers increasingly adopt these innovative strategies, the demand for precision oncology drugs is likely to surge, further driving the Oncology Drugs Market.

Rising Investment in Cancer Research

Rising investment in cancer research is significantly influencing the Oncology Drugs Market. Governments, private organizations, and philanthropic entities are increasingly allocating funds to support cancer research initiatives. In 2023, global funding for cancer research reached approximately 200 billion USD, reflecting a commitment to advancing treatment options and improving patient care. This influx of capital fosters innovation, enabling the development of new oncology drugs and therapies. As research progresses, the Oncology Drugs Market is likely to benefit from a continuous stream of novel treatments, enhancing the overall landscape of cancer care.

Increasing Patient Awareness and Advocacy

Increasing patient awareness and advocacy for cancer treatment options is driving the Oncology Drugs Market. Patients are becoming more informed about their treatment choices, leading to a demand for innovative oncology drugs. Advocacy groups play a pivotal role in educating patients about available therapies and clinical trials, thereby empowering them to make informed decisions. This heightened awareness is likely to translate into increased utilization of oncology drugs, as patients actively seek out the latest treatment options. Consequently, the Oncology Drugs Market is expected to experience growth as more patients engage with healthcare providers to explore advanced therapies.

Regulatory Support and Accelerated Approvals

Regulatory support for oncology drugs is a crucial driver of the Oncology Drugs Market. Regulatory agencies are increasingly implementing expedited approval pathways for innovative cancer therapies, recognizing the urgent need for effective treatments. Initiatives such as the FDA's Breakthrough Therapy Designation and Priority Review programs facilitate faster access to promising drugs. This supportive regulatory environment encourages pharmaceutical companies to invest in oncology research and development, leading to a more robust pipeline of new therapies. As a result, the Oncology Drugs Market is expected to expand, with a growing number of novel drugs entering the market to address unmet medical needs.

Market Segment Insights

By Type: Chemotherapy Drugs (Largest) vs. Immunotherapy Drugs (Fastest-Growing)

In the Oncology Drugs Market, the distribution of market share among the various drug types shows that Chemotherapy Drugs hold the largest share, providing a critical backbone for cancer treatment even as new therapies emerge. Targeted Therapy Drugs follow closely, capitalizing on their specificity to cancer cells, while Immunotherapy Drugs are rapidly gaining traction due to their innovative approach, though they currently hold a smaller share. Hormonal Therapy Drugs, while effective in specific cancers, are relatively limited in their overall oncology market presence compared to these other segments.

Chemotherapy Drugs (Dominant) vs. Immunotherapy Drugs (Emerging)

Chemotherapy Drugs remain the dominant force in the Oncology Drugs Market, known for their ability to target rapidly dividing cancer cells, though they come with significant side effects. Their established use in various forms of cancer treatment provides a sense of reliability and familiarity among oncologists. Conversely, <a href="https://www.marketresearchfuture.com/reports/cancer-immunotherapy-market-592">Cancer Immunotherapy </a>Drugs represent the emerging frontier, leveraging the body's own immune system to fight cancer. Their personalized approach is leading to a revolution in treatment options, particularly for malignancies that have resisted traditional therapies, propelling them into a stronger competitive position. As research advances, Immunotherapy Drugs are set to further transform the landscape of oncology.

By Therapeutic Area: Breast Cancer (Largest) vs. Lung Cancer (Fastest-Growing)

The oncology drugs market is characterized by a varied distribution of market shares among different therapeutic areas. Breast cancer remains the largest segment, driven by its high prevalence and the continuous introduction of innovative therapies. Meanwhile, lung cancer is emerging as the fastest-growing segment due to increasing awareness about early diagnosis and advancements in targeted therapies, which are drawing significant investment from pharmaceutical companies. Furthermore, the oncology market size is influenced by factors such as rising incidences of cancer globally, the increasing number of clinical trials, and a robust pipeline of therapies tailored for specific genetic markers. Prostate and colorectal cancer segments are also gaining attention, albeit at a slower growth pace. As treatment options evolve, the focus remains not just on quantity but also on improving patient outcomes and experiences.

Breast Cancer (Dominant) vs. Lung Cancer (Emerging)

Breast cancer has established itself as the dominant therapeutic area in the oncology drugs market, owing to its highly prevalent nature and extensive research leading to innovative treatment solutions. This includes monoclonal antibodies and hormone therapies that have transformed patient outcomes. The oncology market size is characterized by a wealth of product options, highlighting the commitment to addressing the complexities of breast cancer. In contrast, lung cancer is viewed as an emerging segment, rapidly gaining ground through novel therapies targeting specific genetic mutations and immunotherapy options. With a growing prevalence and rising research investments, stakeholders are increasingly optimistic about the lung cancer therapeutic landscape's potential, positioning it to become a prominent player in the oncology field.

By Route of Administration: Oral (Largest) vs. Intravenous (Fastest-Growing)

The oncology drugs market is characterized by diverse routes of administration, with the oral segment holding the largest market share. Oral administration is preferred due to its convenience and ease of use for patients, allowing for self-administration, minimizing the need for frequent hospital visits. In contrast, the intravenous route is gaining momentum and is noted as the fastest-growing segment. Its position is driven by the need for rapid drug delivery and the increasing complexity of treatment regimens that require precise dosage administration.

Oral (Dominant) vs. Intravenous (Emerging)

The oral route of administration remains dominant in the oncology drugs market as it offers patients the advantages of convenience and adherence. Oral oncology drugs, often in the form of tablets or capsules, empower patients with self-management options while reducing dependence on healthcare facilities. Conversely, intravenous administration is emerging as a crucial method, particularly for aggressive therapies and biologic agents that necessitate immediate systemic exposure. This method ensures controlled drug delivery and a quick onset of action, catering to specific treatments that require precise dosing and monitoring, further catering to the evolving landscape of cancer treatment protocols.

By Patient Demographics: Adult (Largest) vs. Pediatric (Fastest-Growing)

In the Oncology Drugs Market, the adult demographic holds a substantial market share, primarily attributed to the higher prevalence of cancer among older populations. Adults are often diagnosed with a variety of cancer types, which leads to a robust pipeline of oncology drugs tailored specifically for their treatment. Meanwhile, the pediatric demographic is gaining traction as awareness and diagnosis of cancers in younger populations rise, supported by advancements in research and treatment options. Pediatric cancers, though less common, are increasingly prioritized due to specialized therapeutic needs.

Adult (Dominant) vs. Pediatric (Emerging)

The adult segment remains the dominant force in the Oncology Drugs Market, driven by the significant burden of cancer in populations aged 18 and older. This demographic encompasses a wide array of cancers, including lung, colorectal, and breast cancer, each necessitating innovative treatment modalities. Conversely, the pediatric segment, while emerging, showcases a growing focus on developing chemotherapy regimens and targeted therapies specifically designed for children. Enhanced research funding and tailored clinical trials contribute to the rapid development of effective treatments for pediatric cancers, indicating a shift in anticancer drug market dynamics as stakeholders recognize the urgent need for specialized oncology drugs for younger patients.

Get more detailed insights about Oncology Drugs Market Research Report 2035

Regional Insights

North America : Oncology Innovation Leader

North America remains the largest market for oncology drugs, accounting for approximately 45% of the global share. The region's growth is driven by advanced healthcare infrastructure, high R&D investments, and a strong pipeline of innovative therapies. Regulatory support from agencies like the FDA accelerates drug approvals, enhancing anticancer drug market dynamics. The increasing prevalence of cancer and rising healthcare expenditure further fuel demand for oncology treatments. The United States is the leading country in this region, hosting major pharmaceutical companies such as Merck & Co., Bristol-Myers Squibb, and Pfizer. The competitive landscape is characterized by continuous innovation and strategic collaborations among key players. Canada also contributes significantly, focusing on personalized medicine and expanding access to cutting-edge therapies. The presence of robust clinical trial networks supports the development of new oncology drugs.

Europe : Regulatory Framework and Growth

Europe is the second-largest market for oncology drugs, holding around 30% of the global share. The region benefits from a strong regulatory framework that encourages innovation while ensuring patient safety. The European Medicines Agency (EMA) plays a crucial role in expediting the approval of new therapies, particularly for rare cancers. Increasing cancer incidence and a growing aging population are key drivers of oncology drug market growth, alongside rising healthcare investments across member states. Leading countries in Europe include Germany, France, and the United Kingdom, which are home to several prominent pharmaceutical companies like Roche and AstraZeneca. The competitive landscape is marked by a mix of established players and emerging biotech firms focusing on novel therapies. Collaborative efforts between public and private sectors enhance research capabilities, fostering a dynamic environment for oncology drug development.

Asia-Pacific : Rapidly Growing Market

The Asia-Pacific region is witnessing rapid growth in the oncology drugs market, driven by increasing cancer prevalence and improving healthcare infrastructure. This region accounts for approximately 20% of the global oncology drug market share. Countries like China and India are at the forefront, with rising investments in healthcare and a growing focus on research and development. Regulatory bodies are also becoming more supportive, streamlining approval processes for new therapies, which is crucial for anticancer drugs market expansion. China is the largest market in the region, with significant contributions from local pharmaceutical companies and multinational corporations. India follows closely, with a burgeoning biotech sector focused on affordable cancer treatments. The competitive landscape is evolving, with a mix of established players and innovative startups. Collaborations between domestic and international firms are enhancing the development of targeted therapies, positioning the region as a key player in The Oncology Drugs Market.

Middle East and Africa : Emerging Market Potential

The Middle East and Africa (MEA) region is gradually emerging as a potential market for oncology drugs, currently holding about 5% of the global share. The growth is driven by increasing cancer awareness, rising healthcare expenditures, and improving access to treatment. Governments are implementing policies to enhance healthcare infrastructure and attract investments in the pharma oncology sector, which is crucial for anticancer drugs market development. The region's diverse demographics and varying healthcare systems present both challenges and opportunities for oncology drug manufacturers. Leading countries in the MEA region include South Africa, the UAE, and Saudi Arabia, where there is a growing presence of both local and international pharmaceutical companies. The competitive landscape is characterized by partnerships and collaborations aimed at improving access to innovative therapies. As the region continues to develop its healthcare capabilities, the demand for oncology drugs is expected to rise significantly, driven by an increasing patient population and evolving treatment paradigms.

Key Players and Competitive Insights

The Global Oncology Drugs Market is a dynamic segment of the pharma oncology industry characterized by rapid advancements in drug development, regulatory frameworks, and treatment paradigms. The competitive landscape of this market is shaped by various cancer pharmaceutical companies that strive to innovate and offer cutting-edge therapies that address unmet medical needs in cancer care. With an increasing incidence of cancer and the demand for personalized medicine, companies actively engage in research and development, partnerships, and strategic alliances.
This competitive environment is influenced by technological innovation, market access strategies, and the global regulatory landscape, all of which are crucial for success in this specialized and high-stakes market. Companies also face challenges such as pricing pressures, robust competition from generics, and evolving healthcare policies, which require them to adopt agile and adaptive strategies to maintain a competitive edge.Pfizer has established a significant presence in the Global Oncology Drugs Market through its diverse portfolio of oncology products.
The company’s strengths lie in its strong research capabilities and extensive expertise in drug development, enabling it to offer innovative solutions that cater to various cancer types. Pfizer's commitment to personalized medicine sets it apart, as the company invests in targeted therapies and combination treatments aimed at improving patient outcomes. Its pipeline of oncology drugs demonstrates a strong focus on addressing critical areas in cancer treatment, which positions Pfizer favorably in a crowded marketplace. With strategic collaborations and partnerships, Pfizer continues to strengthen its market position while effectively navigating the challenges of pricing and accessibility in the evolving oncology landscape.
Roche, a leading player in the Global Oncology Drugs Market, is renowned for its robust portfolio of targeted therapies and immunotherapies that have transformed cancer treatment. The company's strengths lie in its continuous investment in research and development, along with a comprehensive understanding of molecular biology, which enables it to innovate and bring forth therapies that are tailored to the genetic profiles of tumors. Roche's key oncology products, including those designed for breast cancer, lung cancer, and hematologic malignancies, have solidified its market presence.
The company has engaged in strategic mergers and acquisitions to enhance its offerings and expand its capabilities in oncology. Roche’s focus on diagnostics and personalized treatment approaches ensures comprehensive cancer management, allowing it to maintain a leadership position in the global market while addressing the complexities of cancer care through innovative and effective solutions.

Key Companies in the Oncology Drugs Market include

Industry Developments

Recent developments in the Global Oncology Drugs Market have centered on ongoing advancements in treatment options, with companies like Pfizer, Roche, Gilead Sciences, and Eli Lilly leading the way in innovative therapies. Notably, in September 2023, Bristol Myers Squibb received accelerated approval for its new treatment targeting lung cancer, reflecting an increasing focus on personalized medicine. The market also observed strong growth, driven by rising incidences of cancer globally, which produced a higher demand for novel therapies from major players like Johnson and Johnson and AbbVie.

Significant mergers and acquisitions have been reported, with Novartis acquiring a biotechnology firm specializing in cancer treatments in June 2023 to bolster its oncology portfolio, while Merck and Regeneron Pharmaceuticals announced a strategic collaboration aimed at enhancing their immunotherapy development initiatives in August 2023. Seattle Genetics has also seen a surge in market valuation due to its recent FDA approvals for innovative oncology drugs. The continuous influx of investments and partnerships in the oncology sector signifies a robust and evolving landscape, with companies striving to enhance patient outcomes and expand their therapeutic frameworks globally.

Future Outlook

Oncology Drugs Market Future Outlook

The Oncology Drugs Market is projected to grow at a 14.2% CAGR from 2025 to 2035, driven by advancements in targeted therapies, immunotherapy, and personalized medicine.

New opportunities lie in:

<p>Expansion of telehealth services for oncology consultations Development of AI-driven drug discovery platforms Investment in combination therapy research for enhanced efficacy</p>

By 2035, the Oncology Drugs Market is expected to achieve substantial growth and innovation.

Market Segmentation

Oncology Drugs Market Type Outlook

Chemotherapy Drugs
Targeted Therapy Drugs
Immunotherapy Drugs
Hormonal Therapy Drugs

Oncology Drugs Market Therapeutic Area Outlook

Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Leukemia

Oncology Drugs Market Patient Demographics Outlook

Adult
Pediatric
Geriatric

Oncology Drugs Market Route of Administration Outlook

Oral
Intravenous
Subcutaneous
Intramuscular

Report Scope

MARKET SIZE 2024	177.1(USD Billion)
MARKET SIZE 2025	202.26 (USD Billion)
MARKET SIZE 2035	763.21 (USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	14.2% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Roche (CH), Bristol-Myers Squibb (US), Merck & Co. (US), Novartis (CH), Pfizer (US), AstraZeneca (GB), Johnson & Johnson (US), Amgen (US), Gilead Sciences (US)
Segments Covered	Drug Type, Therapeutic Area, Route of Administration, Patient Demographics, Regional
Key Market Opportunities	Advancements in personalized medicine and immunotherapy are reshaping the Oncology Drugs Market landscape.
Key Market Dynamics	Rising demand for targeted therapies drives innovation and competition in the oncology drugs market.
Countries Covered	North America, Europe, APAC, South America, MEA